MAPT and Creutzfeldt Jacob disease: When we assessed the biomarkers' diagnostic performance in distinguishing between patients with CJD and those with non-neurodegenerative np-RPD, CSF SNAP-25 outperformed all the other single and p-tau-adjusted biomarkers (AUC 0.887 [0.850–0.925]) (SNAP-25 vs. t-tau, P = 0.0003; SNAP-25 vs. t-tau/p-tau, P = 0.0002; SNAP-25 vs 14–3-3, P < 0.0001; SNAP-25 vs. NfL, P < 0.0001) (Table 2).